More From the CardioNerds
Ticagrelor monotherapy after dual-antiplatelet therapy following PCI with DES yields superior outcomes. Dr. Clark details the MINT trial, which addressed the accurate transfusion threshold in patients with acute MI and anemia. Dr. Okumus details the ORBITA-2 trial, which marked a significant advancement in understanding and treating stable angina. CardioNerds correspondent Dr. Ahmed Ghoneem details the positive effects of semaglutide, as demonstrated in the SELECT trial. CardioNerds correspondent Dr. Christian Inchaustegui details the findings of ARIES-HM3, presented at AHA 2023. In low-risk patients with symptomatic AS, TAVR is safe, effective, and durable up to 5 years.